Kebilidi is the first gene therapy approved by the FDA for administration directly into the brain, given via a cannula during ...

The move reflects a growing interest in the PD-1 and VEGF pathways in the cancer space. Earlier this year, Summit ...

The Precision Health and Longevity Summit 2024, the first event of its kind in Canada, will take place on November 15-16, 2024, at The Westin Hotel in Calgary, Alberta. This groundbreaking event will ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...

On Monday, Summit Therapeutics Inc (SMMT) stock saw a modest uptick, ending the day at $21.77 which represents a slight increase of $0.36 or 1.68% from the prior close of $21.41. The stock opened at ...

Compass Pathways in a panel discussion at the FT Global Pharma and Biotech Summit on 7 November. Recent developments, such as ...

AppLovin's stock had its best day ever Thursday, rising 46% following the company's latest earnings, and it gained another 18% in Friday's session. That could reflect investor perception of how far ...

Biopharma stocks are rarely suitable for short-term investing, so hold onto them. Summit Therapeutics may have a powerful new ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) have earned an average recommendation of “Buy” from the nine analysts that are covering the firm, Marketbeat Ratings reports. Eight ...